1. N.C.E.P. Third report of the National Cholesterol Education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treament panel III). Final report. 2002.
2. Hayden MR. Overview and new insights into the metabolic syndrome: Risk factors and emerging variables in the development of type 2 diabetes and cerebrocardiovascular disease. Medicina 2023; 59: 561-606.
3. Wan Mahmud Sabri WMN, Mohamed RZ, Yaacob NM, Hussain S. Prevalence of metabolic syndrome and its associated risk factors in pediatric obesity. J ASEAN Fed Endocr Soc 2022; 37: 24-30.
4. Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, Nkeck JR, Nyaga UF, Ngouo AT, et al. Geographic distribution of metabolic syndrome and its components in the general adult population: A meta-analysis of global data from 28 million individuals. Diabetes Res Clin Pract 2022; 188:109924.
5. Chew NW, Ng CH, Tan DJH, Kong G, Lin C, Chin YH, et al. The global burden of metabolic disease: Data from 2000 to 2019. Cell Metab 2023; 35: 414-428.
6. Fornari E, Maffeis C. Treatment of metabolic syndrome in children. Front Endocrinol 2019; 10:702-710.
7. Lillich FF, Imig JD, Proschak E. Multi-Target Approaches in Metabolic Syndrome. Front Pharmacol 2021:11: 554961-554978.
8. Ibrahim KG, Mukonowenzou NC, Usman D, Adeshina KA, Erlwanger KH. The potential of Artemisia species for use as broad-spectrum agents in the management of metabolic syndrome: A review. Arch Physiol Biochem 2023; 129: 752-770.
9.World Health Organisation. WHO global report on traditional and complementary medicine 2019. Geneva: World Health Organization; 2019.
10. Ibrahim KG, Adeshina KA, Bello MB, Malami I, Abubakar B, Abubakar MB, et al. Prophylactic use of natural products against developmentally programmed metabolic syndrome. Planta Med 2022; 88: 650-663.
11. Ravi Y, Vethamoni PI, Saxena S, Velmurugan S, Santhanakrishnan V, Raveendran M. Effect of various extraction solvents on the bioactive compounds and antioxidant activity of Nigella sativa L. seeds. Int J Phytomed Rel Ind 2023; 15:139-144.
12. Isaev NK, Genrikhs EE, Stelmashook EV. Antioxidant thymoquinone and its potential in the treatment of neurological diseases. Antioxidants 2023; 12:433-446.
13. Abo Mansour HE, Elberri AI, Ghoneim ME-S, Samman WA, Alhaddad AA, Abdallah MS, et al. The potential neuroprotective effect of thymoquinone on scopolamine-induced in vivo alzheimer’s disease-like condition: Mechanistic insights. Molecules 2023; 28:6566-6585.
14. Kwan K, Han AY, Mukdad L, Barragan F, Selim O, Alhiyari Y, et al. Anticancer effects of thymoquinone in head and neck squamous cell carcinoma: A scoping review. Laryngoscope Investig Otolaryngol 2023; 8:876-885.
15. Shoaib A, Javed S, Wahab S, Azmi L, Tabish M, Sultan MH, et al. Cellular, molecular, pharmacological, and nano-formulation aspects of thymoquinone-a potent natural antiviral agent. Molecules 2023; 28:5435-5453.
16. Rathod S, Agrawal Y, Sherikar A, Nakhate KT, Patil CR, Nagoor Meeran M, et al. Thymoquinone produces cardioprotective effect in β-receptor stimulated myocardial infarcted rats via subsiding oxidative stress and inflammation. Nutrients 2022; 14:2742-2754.
17. Alanazi S, Alsaqer R, Alsaeed F, Almakhaytah R, Buwashl N, Mohamed M, et al. Studying the actions of sage and thymoquinone combination on metabolic syndrome induced by high-fat diet in rats. Eur Rev Med Pharmacol Sci 2023; 27: 2404-2418.
18. Nilsson PM, Tuomilehto J, Rydén L. The metabolic syndrome–What is it and how should it be managed? Eur J Prev Cardiol 2019; 26: 33-46.
19. Ong YS, Saiful Yazan L, Ng WK, Noordin MM, Sapuan S, Foo JB, et al. Acute and subacute toxicity profiles of thymoquinone-loaded nanostructured lipid carrier in BALB/c mice. Int J Nanomedicine 2016; 11:5905-5915.
20. Mashayekhi-Sardoo H, Rezaee R, Karimi G. An overview of in vivo toxicological profile of thymoquinone. Toxin Reviews 2020; 39:115-122.
21. Salehi B, Quispe C, Imran M, Ul-Haq I, Živković J, Abu-Reidah IM, et al. Nigella plants–Traditional uses, bioactive phytoconstituents, preclinical and clinical studies. Front Pharmacol 2021; 12: 625386-625411.
22. Tiwari G, Gupta M, Devhare LD, Tiwari R. Therapeutic and phytochemical properties of thymoquinone derived from Nigella sativa. Curr Drug Res Rev 2024; 16:145-156. 
23.Taleuzzaman M, Ahmad A, Ahmad M, Gilani SJ. Nigella Sativa: Its Ethnobotany, Phytochemistry, and Pharmacology.  In: Edible Plants in Health and Diseases: Volume II: Phytochemical and Pharmacological Properties: Springer; 2022. p. 175-203.
24. Ahmad A, Husain A, Mujeeb M, Khan SA, Najmi AK, Siddique NA, et al. A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed 2013; 3: 337-352.
25. Sharma P, Yelne M, Dennis T, Joshi A, Billore K. Database on medicinal plants used in Ayurveda. New Delhi: 2005; 2000: 420-440.
26. Ahmad A, Mishra RK, Vyawahare A, Kumar A, Rehman MU, Qamar W, et al. Thymoquinone (2-Isopropyl-5-methyl-1, 4-benzoquinone) as a chemopreventive/anticancer agent: Chemistry and biological effects. Saudi Pharm J 2019; 27:1113-1126.
27.Ramadan MF. Chapter 30 - Black Cumin (Nigella sativa) Oils. In: Preedy VR, editor. Essential Oils in Food Preservation, Flavor and Safety. San Diego: Academic Press; 2016. p. 269-275.
28. Alkharfy KM, Ahmad A, Khan RM, Al-Shagha WM. Pharmacokinetic plasma behaviors of intravenous and oral bioavailability of thymoquinone in a rabbit model. Eur J Drug Metab Pharmacokinet 2015; 40: 319-323.
29. Salmani JMM, Asghar S, Lv H, Zhou J. Aqueous solubility and degradation kinetics of the phytochemical anticancer thymoquinone; probing the effects of solvents, pH and light.  Molecules 2014; 19: 5925-5939.
30. Ahmad A, Raish M, Alkharfy KM, Alsarra IA, Khan A, Ahad A, et al. Solubility, solubility parameters and solution thermodynamics of thymoquinone in different mono solvents. J Mol Liq 2018; 272:912-918.
31. Mohammadabadi MR, Mozafari MR. Enhanced efficacy and bioavailability of thymoquinone using nanoliposomal dosage form. J Drug Deliv Sci Technol 2018; 47:445-453.
32. Khalife KH, Lupidi G. Nonenzymatic reduction of thymoquinone in physiological conditions. Free Radic Res 2007; 41:153-161.
33. Hossain MS, Sharfaraz A, Dutta A, Ahsan A, Masud MA, Ahmed IA, et al. A review of ethnobotany, phytochemistry, antimicrobial pharmacology and toxicology of Nigella sativa L. Biomed Pharmacother 2021; 143:112182-112206.
34. Jazieh AR, Al Sudairy R, Abulkhair O, Alaskar A, Al Safi F, Sheblaq N, et al. Use of complementary and alternative medicine by patients with cancer in Saudi Arabia. J Altern Complement Med 2012; 18:1045-1049.
35. Goyal SN, Prajapati CP, Gore PR, Patil CR, Mahajan UB, Sharma C, et al. Therapeutic potential and pharmaceutical development of thymoquinone: A multitargeted molecule of natural origin. Front Pharmacol 2017; 8: 656-674.
36. Darakhshan S, Pour AB, Colagar AH, Sisakhtnezhad S. Thymoquinone and its therapeutic potentials. Pharmacol Res 2015; 95:138-158.
37. Rifaioglu MM, Nacar A, Yuksel R, Yonden Z, Karcioglu M, Zorba OU, et al. Antioxidative and anti-inflammatory effect of thymoquinone in an acute Pseudomonas prostatitis rat model. Urol Int 2013; 91:474-481.
38. Kouidhi B, Zmantar T, Jrah H, Souiden Y, Chaieb K, Mahdouani K, et al. Antibacterial and resistance-modifying activities of thymoquinone against oral pathogens. Ann Clin Microbiol  Antimicrob 2011; 10:1-7.
39. Lin X, Li H. Obesity: Epidemiology, pathophysiology, and therapeutics. Front Endocrinol 2021; 12:706978-706986.
40. Tzenios N. Obesity as a risk factor for cancer. EPRA Int J Res Dev (IJRD) 2023; 8:101-104.
41. Bray GA. Medical consequences of obesity. J Clin Endocrinol Metab 2004; 89: 2583-2589.
42. Sadler JR, Thapaliya G, Ranganath K, Gabay A, Chen L, Smith KR, et al. Paediatric obesity and metabolic syndrome associations with cognition and the brain in youth: Current evidence and future directions. Pediatr Obes 2023;18:e13042-13083.
43.Lobstein T, Brinsden H, Neveux M. World Obesity Atlas 2022. London, United Kingdom: 2022.
44. Harphoush S, Wu G, Qiuli G, Zaitoun M, Ghanem M, Shi Y, et al. Thymoquinone ameliorates obesity-induced metabolic dysfunction, improves reproductive efficiency exhibiting a dose-organ relationship. Sys Biol Reprod Med 2019; 65:367-382.
45. Beena T, Jesil MA, Harikumar K. Cross-talk between AMP-activated protein kinase and the sonic hedgehog pathway in the high-fat diet triggered colorectal cancer. Arch Biochem Biophys 2023; 735:109500.
46. Chen R, Lai X, Xiang L, Li Q, Sun L, Lai Z, et al. Aged green tea reduces high-fat diet-induced fat accumulation and inflammation via activating the AMP-activated protein kinase signaling pathway. Food Nutr Res 2022; 66:2022-2033.
47. Shahbodi M, Emami SA, Javadi B, Tayarani-Najaran Z. Effects of thymoquinone on adipocyte differentiation in human adipose-derived stem cells. Cell Biochem Biophys 2022; 80:771-779.
48. Sugimoto R, Ishibashi-Ohgo N, Atsuji K, Miwa Y, Iwata O, Nakashima A, et al. Euglena extract suppresses adipocyte-differentiation in human adipose-derived stem cells. PloS One 2018; 13:e0192404.
49. Kaviani F, Razavi BM, Mohsenzadeh MS, Rameshrad M, Hosseinzadeh H. Thymoquinone attenuates olanzapine-induced metabolic disorders in rats. Mol Biol Rep 2023;50:8925-8935.
50. Tschop M, Smiley D, Heiman M. Ghrelin induces adiposity in rodents. Nature 2000; 407:908-913.
51. Tütüncü Ş, Delice N. Effect of thymoquinone on ghrelin expression in rat stomach. J Appl Biol Sci 2023; 17:257-265.
52. Badr G, Mahmoud MH, Farhat K, Waly H, Al-Abdin OZ, Rabah DM. Maternal supplementation of diabetic mice with thymoquinone protects their offspring from abnormal obesity and diabetes by modulating their lipid profile and free radical production and restoring lymphocyte proliferation via PI3K/AKT signaling. Lipids Health Dis 2013:12:37-47.
53. Tüfek NH, Altunkaynak ME, Altunkaynak BZ, Kaplan S. Effects of thymoquinone on testicular structure and sperm production in male obese rats. Sys Biol Reprod Med 2015; 61:194-204.
54. Shen HH, Peterson SJ, Bellner L, Choudhary A, Levy L, Gancz L, et al. Cold-pressed Nigella sativa oil standardized to 3% thymoquinone potentiates omega-3 protection against obesity-induced oxidative stress, inflammation, and markers of insulin resistance accompanied with conversion of white to beige fat in mice. Antioxidants 2020;9:489-506.
55. Scarano F, Gliozzi M, Zito MC, Guarnieri L, Carresi C, Macrì R, et al. Potential of nutraceutical supplementation in the modulation of white and brown fat tissues in obesity-associated disorders: role of inflammatory signalling. Int J Mol Sci 2021; 22:3351-3372.
56. Bashir KMI, Kim JW, Kim J-K, Chun Y-S, Choi J-S, Ku S-K. Efficacy confirmation test of black cumin (Nigella sativa L.) seeds extract using a high-fat diet mouse model. Metabolites 2023; 13:501-522.
57. Mostafa TM, Hegazy SK, Elnaidany SS, Shehabeldin WA, Sawan ES. Nigella sativa as a promising intervention for metabolic and inflammatory disorders in obese prediabetic subjects: a comparative study of Nigella sativa versus both lifestyle modification and metformin. J Diabetes Complications 2021; 35:107947.
58. Mahdavi R, Namazi N, Alizadeh M, Farajnia S. Nigella sativa oil with a calorie-restricted diet can improve biomarkers of systemic inflammation in obese women: A randomized double-blind, placebo-controlled clinical trial. J Clin lipidol 2016; 10:1203-1211.
59. Datau E, Surachmanto EE, Pandelaki K, Langi J. Efficacy of Nigella sativa on serum free testosterone and metabolic disturbances in central obese male. Acta Medica Indonesiana 2010; 42:130-134.
60. Pei Z-W, Guo Y, Zhu H-L, Dong M, Zhang Q, Wang F. Thymoquinone protects against hyperlipidemia-induced cardiac damage in low-density lipoprotein receptor-deficient (LDL-R-/-) mice via its anti-inflammatory and antipyroptotic effects. Biomed Res Int 2020; 2020:4878704-4878712.
61. Al Asoom L. Is Nigella sativa an effective bodyweight lowering agent and a mitigator of obesity risk? A literature review. Vasc Health Risk Manag 2022;18: 495-505.
62. Mahmoudi A, Samani KG, Farrokhi E, Heidarian E. Effects of Nigella sativa extracts on the lipid profile and uncoupling protein-1 gene expression in Brown adipose tissue of mice. Adv Biomed Res 2018; 7:121-126.
63. Fadishei M, Ghasemzadeh Rahbardar M, Imenshahidi M, Mohajeri A, Razavi BM, Hosseinzadeh H. Effects of Nigella sativa oil and thymoquinone against bisphenol A‐induced metabolic disorder in rats. Phytother Res 2021; 35:2005-2024.
64. Prabhakar P, Reeta KH, Maulik SK, Dinda AK, Gupta YK. Protective effect of thymoquinone against high-fructose diet-induced metabolic syndrome in rats. Eur J Nutr 2015; 54:1117-1127.
65. Nader MA, El-Agamy DS, Suddek GM. Protective effects of propolis and thymoquinone on development of atherosclerosis in cholesterol-fed rabbits. Arch Pharm Res 2010; 33:637-643.
66. El-Shemi AG, Kensara OA, Alsaegh A, Mukhtar MH. Pharmacotherapy with thymoquinone improved pancreatic β-cell integrity and functional activity, enhanced islets revascularization, and alleviated metabolic and hepato-renal disturbances in streptozotocin-induced diabetes in rats. Pharmacology 2017; 101: 9-21.
67. Abdelrazek H, Kilany OE, Muhammad MA, Tag HM, Abdelazim AM. Black seed thymoquinone improved insulin secretion, hepatic glycogen storage, and oxidative stress in streptozotocin-induced diabetic male Wistar rats. Oxid Med Cell Longev 2018; 2018:8104165-8104174.
68. Alshahrani S, Anwer T, Alam MF, Ahmed RA, Khan G, Sivakumar SM, et al. Effect of thymoquinone on high fat diet and STZ‐induced experimental type 2 diabetes: A mechanistic insight by in vivo and in silico studies. J Food Biochem 2021; 45:e13807.
69. Rani R, Dahiya S, Dhingra D, Dilbaghi N, Kaushik A, Kim K-H, et al. Antidiabetic activity enhancement in streptozotocin+ nicotinamide–induced diabetic rats through combinational polymeric nanoformulation. Int J Nanomed 2019; 14: 4383-4395.
70. Al-Naqeep G, Ismail M, Yazan LS. Effects of thymoquinone rich fraction and thymoquinone on plasma lipoprotein levels and hepatic low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase genes expression. J Funct Foods 2009; 1:298-303.
71. Ahmad S, Beg ZH. Hypolipidemic and antioxidant activities of thymoquinone and limonene in atherogenic suspension fed rats. Food Chem 2013; 138:1116-1124.
72. Li C, Chen JW, Ding FH, Shen Y, Liu ZH, Wang F, et al. Relationship of high-density lipoprotein-associated arylesterase activity to systolic heart failure in patients with and without type 2 diabetes. Sci Rep 2019; 9:5979-5986.
73. Ahmad S, Beg ZH. Elucidation of mechanisms of actions of thymoquinone-enriched methanolic and volatile oil extracts from Nigella sativa against cardiovascular risk parameters in experimental hyperlipidemia. Lipids Health Dis 2013; 12: 86-97.
74. Xu J, Zhu L, Liu H, Li M, Liu Y, Yang F, et al. Thymoquinone reduces cardiac damage caused by hypercholesterolemia in apolipoprotein E-deficient mice. Lipids Health Dis 2018; 17:1-9.
75. Akhmedov A, Sawamura T, Chen C-H, Kraler S, Vdovenko D, Lüscher TF. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease. Eur Heart J 2021; 42:1797-1807.
76. Shoaei‐Hagh P, Kamelan Kafi F, Najafi S, Zamanzadeh M, Heidari Bakavoli A, Ramezani J, et al. A randomized, double‐blind, placebo‐controlled, clinical trial to evaluate the benefits of Nigella sativa seeds oil in reducing cardiovascular risks in hypertensive patients. Phytother Res 2021; 35:4388-4400.
77. Thomas JV, Mohan M, Prabhakaran P, Maliakel B, Krishnakumar I. A phase I clinical trial to evaluate the safety of thymoquinone-rich black cumin oil (BlaQmax®) on healthy subjects: Randomized, double-blinded, placebo-controlled prospective study. Toxicol Rep 2022; 9:999-1007.
78. Rashidmayvan M, Mohammadshahi M, Seyedian SS, Haghighizadeh MH. The effect of Nigella sativa oil on serum levels of inflammatory markers, liver enzymes, lipid profile, insulin and fasting blood sugar in patients with non-alcoholic fatty liver. J Diabetes Metab Disord 2019; 18:453-459.
79. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114: 555-576.
80. da Silva AA, do Carmo JM, Li X, Wang Z, Mouton AJ, Hall JE. Role of hyperinsulinemia and insulin resistance in hypertension: metabolic syndrome revisited. Can J Cardiol 2020; 36: 671-682.
81. Soleimani M, Barone S, Luo H, Zahedi K. Pathogenesis of hypertension in metabolic syndrome: The role of fructose and salt. Int J Mol Sci 2023; 24:4294-4303.
82. Suvila K, McCabe EL, Lehtonen A, Ebinger JE, Lima JA, Cheng S, et al. Early onset hypertension is associated with hypertensive end-organ damage already by midlife. Hypertension 2019; 74:305-312.
83. Azzubaidi MS, Noor NM, Mizher HA. Antihypertensive and antihyperlipidemic activities of thymoquinone in l-name hypertensive rats. J Hypertens 2015; 33: e7-e8.
84. Jaarin K, Foong WD, Yeoh MH, Kamarul ZYN, Qodriyah HMS, Azman A, et al. Mechanisms of the antihypertensive effects of Nigella sativa oil in L-NAME-induced hypertensive rats. Clinics 2015; 70:751-757.
85. Azzubaidi MS, Mizher H, Alattraqchi AG. Hypotensive activity of thymoquinone in normotensive rats and its receptor mechanisms. Int J Pharm Pharm Sci 2017; 9:216-218. 
86. Najmi A, Nasiruddin M, Khan R, Haque SF. Indigenous herbal product Nigella sativa proved effective as an antihypertensive in metabolic syndrome. Asian J Pharm Clin Res 2013; 6: 61-64.
87. Khattab MM, Nagi MN. Thymoquinone supplementation attenuates hypertension and renal damage in nitric oxide deficient hypertensive rats. Phytother Res 2007; 21:410-414.
88. Enayatfard L, Mohebbati R, Niazmand S, Hosseini M, Shafei MN. The standardized extract of Nigella sativa and its major ingredient, thymoquinone, ameliorates angiotensin II-induced hypertension in rats. J Basic  Clin Physiol Pharmacol 2019; 30:51-58.
89. Zhu N, Zhao X, Xiang Y, Ye S, Huang J, Hu W, et al. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats. Int J Cardiol 2016; 221:587-596.
90. Dera AA, Rajagopalan P, Alfhili MA, Ahmed I, Chandramoorthy HC. Thymoquinone attenuates oxidative stress of kidney mitochondria and exerts nephroprotective effects in oxonic acid-induced hyperuricemia rats. BioFactors 2020; 46:292-300.
91. Sakr H. Effect of thymoquinone [an active constituent of Nigella sative seeds] on blood pressure and respiration of DOCA-salt hypertensive and normotensive rats. Bull Alex Fac Med 1994; 30:147-154.
92. Fallah Huseini H, Amini M, Mohtashami R, Ghamarchehre M, Sadeqhi Z, Kianbakht S, et al. Blood pressure lowering effect of Nigella sativa L. seed oil in healthy volunteers: A randomized, double‐blind, placebo‐controlled clinical trial. Phytother Res 2013; 27:1849-1853.
93. Dehkordi FR, Kamkhah AF. Antihypertensive effect of Nigella sativa seed extract in patients with mild hypertension. Fundam Clin Pharmacol 2008; 22:447-452.
94. Qidwai W, Hamza HB, Qureshi R, Gilani A. Effectiveness, safety, and tolerability of powdered Nigella sativa (kalonji) seed in capsules on serum lipid levels, blood sugar, blood pressure, and body weight in adults: results of a randomized, double-blind controlled trial. J Altern Complement Med 2009; 15:639-644.
95. Shah AS, Khan GM, Badshah A, Shah SU, Shah KU, Mirza SA, et al. Nigella sativa provides protection against metabolic syndrome. Afr J Biotechnol 2012; 11:10919-10925.
96. Saumi R, Bukhari A. Phytotherapy Nigella sativa lowers blood pressure in patients with stage 1 hypertension. J Hypertens 2015; 33:e43.
97. Badar A, Kaatabi H, Bamosa A, Al-Elq A, Abou-Hozaifa B, Lebda F, et al. Effect of Nigella sativa supplementation over a one-year period on lipid levels, blood pressure and heart rate in type-2 diabetic patients receiving oral hypoglycemic agents: nonrandomized clinical trial. Ann Saudi Med 2017; 37:56-63.
98. Rizka A, Setiati S, Lydia A, Dewiasty E. Effect of Nigella sativa seed extract for hypertension in elderly: a double-blind, randomized controlled trial. Acta Med Indones 2017; 49:307-313.
99. Li M, Chi X, Wang Y, Setrerrahmane S, Xie W, Xu H. Trends in insulin resistance: insights into mechanisms and therapeutic strategy. Signal Transduct Target Ther 2022; 7:216-240.
100. Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A. Pathophysiology of physical inactivity-dependent insulin resistance: A theoretical mechanistic review emphasizing clinical evidence. J Diabetes Res 2021; 2021:7796727-7796738.
101. Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 2020; 21:6275-6309.
102. Zhao X, An X, Yang C, Sun W, Ji H, Lian F. The crucial role and mechanism of insulin resistance in metabolic disease. Front Endocrinol 2023; 14:1149239-1149262.
103. Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity/resistance. Indian J Endocrinol Metab 2015; 19:160-164.
104. Shaukat A, Zaidi A, Anwar H, Kizilbash N. Mechanism of the antidiabetic action of Nigella sativa and Thymoquinone: A review. Front Nutr 2023; 10 :1126272-1126299.
105. Gandhi GR, Hillary VE, Antony PJ, Zhong LL, Yogesh D, Krishnakumar NM, et al. A systematic review on anti-diabetic plant essential oil compounds: Dietary sources, effects, molecular mechanisms, and safety. Crit Rev Food Sci Nutr 2023;1:1-20.
106. Estrada-Soto S, Ornelas-Mendoza K, Navarrete-Vázquez G, Chávez-Silva F, Almanza-Pérez JC, Villalobos-Molina R, et al. Insulin sensitization by PPARγ and GLUT-4 overexpression/translocation mediates the antidiabetic effect of plantago australis. Pharmaceuticals 2023; 16: 535-559.
107. Varga T, Czimmerer Z, Nagy L. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation. Biochim Biophys Acta 2011; 1812: 1007-1022.
108. Karandrea S, Yin H, Liang X, Slitt AL, Heart EA. Thymoquinone ameliorates diabetic phenotype in Diet-Induced Obesity mice via activation of SIRT-1-dependent pathways. PloS One 2017; 12:e0185374.
109. Chandra S, Murthy SN, Mondal D, Agrawal KC. Therapeutic effects of Nigella sativa on chronic HAART-induced hyperinsulinemia in rats. Can J Physiol Pharmacol 2009; 87:300-309.
110. Liu H, Liu HY, Jiang YN, Li N. Protective effect of thymoquinone improves cardiovascular function, and attenuates oxidative stress, inflammation and apoptosis by mediating the PI3K/Akt pathway in diabetic rats. Mol Med Rep 2016; 13: 2836-2842.
111. Awad AS, Abd Al Haleem EN, El-Bakly WM, Sherief MA. Thymoquinone alleviates nonalcoholic fatty liver disease in rats via suppression of oxidative stress, inflammation, apoptosis. Naunyn Schmiedebergs Arch Pharmacol 2016; 389:381-391.
112. Kwon H, Pessin JE. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne) 2013; 4:71-83.
113. Huwait E, Al-Gharawi N, Al-Ghamdi MA, Gari M, Prola A, Natesan Pushparaj P, et al. Thymoquinone (TQ) inhibits inflammation and migration of THP-1 macrophages: Mechanistic insights into the prevention of atherosclerosis using in-vitro and in-silico analysis. Curr Issues Mol Biol 2022; 44:1740-1753.
114. Mahomoodally MF, Aumeeruddy MZ, Legoabe LJ, Montesano D, Zengin G. Nigella sativa L. and its active compound thymoquinone in the clinical management of diabetes: A systematic review. Int J Mol Sci 2022; 23:12111-12136.
115. Salem ML. Immunomodulatory and therapeutic properties of the Nigella sativa L. seed. Int Immunopharmacol 2005; 5:1749-1770.
116. Khader M, Bresgen N, Eckl P. In vitro toxicological properties of thymoquinone. Food Chem Toxicol 2009; 47:129-133.
117. Farooq J, Sultana R, Taj T, Asdaq SMB, Alsalman AJ, Mohaini MA, et al. Insights into the protective effects of thymoquinone against toxicities induced by chemotherapeutic agents. Molecules 2021; 27:226-240.
118. Shakeri F, Gholamnezhad Z, Mégarbane B, Rezaee R, Boskabady MH. Gastrointestinal effects of Nigella sativa and its main constituent, thymoquinone: A review. Avicenna J Phytomed  2016; 6: 9-20.